GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE™ Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE™ Product Candidates

BEVERLY HILLS, Calif., May 12, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…

GT Biopharma to Present at The Virtual 33rd Annual Roth Conference

BEVERLY HILLS, Calif., March 10, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…

Personalized Medicine Is The Next Big Trend For Biotech Stocks & 1 Company Could Radically Disrupt The Industry

Personalized Medicine Should Be At The Top Of Your List In 2021 & Here’s Why

GT Biopharma Announces Dr. Greg Berk, M.D. Joins Board of Directors

BEVERLY HILLS, CA / ACCESSWIRE / November 19, 2020 / GT Biopharma,…

GT Biopharma Appoints Michael Handelman, CPA as Chief Financial Officer

BEVERLY HILLS, CA / ACCESSWIRE / November 18, 2020 / GT Biopharma,…

GT Biopharma Announces Former Abraxis CEO, Bruce J. Wendel as Vice Chairman of GTBP Board of Directors

BEVERLY HILLS, CA / ACCESSWIRE / November 17, 2020 / PGT Biopharma,…

GT Biopharma Announces Publication of Trike(TM) Results Targeting Multiple B7H3 Positive Cancers

BEVERLY HILLS, CA / ACCESSWIRE / October 21, 2020 / GT Biopharma, Inc.…